AHC
BMY.RT

Anderson Hoagland & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Anderson Hoagland & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-108,255
Closed -$316K – 79
2020
Q1 		$316K Buy
108,255
+89,645
+482% +$295K 0.2% 76
2019
Q4 		$53K Buy
+18,610
New +$48.4K 0.03% 84

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Anderson Hoagland & Co's BMY.RT Position: Q2 2020 in Review

Anderson Hoagland & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020, closing a stake of 108,255 shares — an estimated $316K sold.

Anderson Hoagland & Co first reported a position in BMY.RT in Q4 2019 and held it in 2 quarters. The position peaked at $316K in Q1 2020. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • Anderson Hoagland & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • Anderson Hoagland & Co sold 108,255 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2020, an estimated $316K.
  • Anderson Hoagland & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 2 quarters.
  • Anderson Hoagland & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $316K in Q1 2020.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on Anderson Hoagland & Co's 13F filing for Q2 2020, filed 6 Jul 2020.